logo
Plus   Neg
Share
Email

Novo Nordisk, Teva Settle US Patent Litigation For Victoza - Quick Facts

Novo Nordisk (NVO) announced that a settlement between the company and Teva Pharmaceuticals USA, Inc. has been reached on the US patent litigation case for Victoza (liraglutide). Consequently, Teva is licensed to launch a generic version of Victoza as of 22 December 2023.

The company noted that, under certain circumstances Teva could launch a generic version of Victoza earlier, but not before 22 March 2023, unless the Victoza patents are no longer in force or there is another generic version of Victoza on the market.

For comments and feedback contact: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Target Corp. has introduced Everspring, a new household essentials brand comprised of more than 70 household essentials items that includes bio-based or recycled materials or natural fibers. The new, in-house brand has been designed by Target with sustainability in mind and is part of its efforts to make products that include ingredients derived from plants or renewable materials more accessible. While reporting financial results for the first quarter, American Express Co. (AXP) on Thursday affirmed its earnings and revenue growth guidance for the full-year 2019. For fiscal 2019, the company continues to project earnings in the range of $7.64 to $8.14 per share and adjusted earnings in the... While reporting financial results for the first quarter, Honeywell international Inc. (HON) on Thursday raised its earnings and sales outlook for the full-year 2019. For fiscal 2019, the company raised its earnings outlook to a range of $7.90 to $8.15 per share from the previous guidance range of...
Follow RTT